npj Breast Cancer (Mar 2025)

Real-World outcomes with sacituzumab govitecan among breast cancer patients with central nervous system metastases

  • Thomas Grinda,
  • Stefania Morganti,
  • Liangge Hsu,
  • Tae-Kyung Yoo,
  • Ross J. Kusmick,
  • Ayal A. Aizer,
  • Antonio Giordano,
  • Jose P. Leone,
  • Melissa Hughes,
  • Sara M. Tolaney,
  • Nancy U. Lin,
  • Sarah L. Sammons

DOI
https://doi.org/10.1038/s41523-025-00736-9
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 6

Abstract

Read online

Abstract Central nervous system (CNS) metastases are associated with poor prognosis in patients with metastatic breast cancer (MBC). In this retrospective study, we investigated the activity of sacituzumab govitecan (SG) in 33 patients with HER2-negative MBC and CNS metastases, including active, stable/treated, and leptomeningeal disease (LMD). SG demonstrated a modest CNS objective response rate of 4/30 (13%) and median CNS-progression-free survival of 2.9 months (95%CI:2.0–4.3) in a heavily pretreated population.